Phase 4 N=291 Efficacy and Safety of Single, Low-dose Dexamethasone in Patients After Total Knee Arthroplasty
Osteoarthritis, Knee
Primary: Incidence of Nausea and Vomiting — 24; 40 percentage of participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
Friedreich Ataxia
Primary: Creatine Rephosphorylation Rate Post Exercise — 0.024; 0.029; 0.022; 0.029 pH per second — p=0.9133
Phase 4 N=32 12- Week Open Label Treatment of Refractory Bipolar Depression
Bipolar Disorder
Primary: Primary Measure:Reduction in Depression Symptoms — 16 participants
Phase 3 N=156 A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Pain · Cancer
Primary: Percentage of Participants Achieving Dose Titration Success — 80.60 Percentage of participants
Phase 2 N=11 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Phase 3 N=1,356 Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
Influenza
Primary: Immunogenicity, Assessed by the Haemagglutination (HI) Test — 97.2; 89.7; 92.7; 90.5 percentage of participants — p=0.0036
Phase 2 N=12 Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Participants Responding to the Vaccine — 6 Participants
Phase 2 N=137 A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Breast Cancer
Primary: Progression-free Survival (PFS) by the Investigator Using Modified Response Evaluation Criteria In Solid Tumors (RECIST) — 14.2; 9.2 Months
Phase 1 N=110 Safety and Efficacy of AL-53817 Nasal Spray Solution
Nasal Allergies · Allergies
Primary: Number of Adverse Events in Stage A — 9; 3; 0; 0 Adverse Events
Phase 4 N=99 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration
Primary: Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12 — -0.18; -0.12 logMAR
Phase 3 N=205 Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V
Influenza
Primary: Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza…
Phase 3 N=4,560 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Percentage of Women With Serious Adverse Events — 0.0 percentage of women
N/A N=74 Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure
Breast Hypertrophy · Abdominal Elastosis · Breast Reconstruction
Primary: Scar Quality at 6 Months Postoperative — 3.8; 2.6 units on a scale
Phase 3 N=97 A Study in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone — -0.01; 0.00 ratio — p=0.121
Phase 3 N=921 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Glioblastoma
Primary: Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator — 10.6; 6.2 Months — p=<0.0001